Lilly's Olumiant Is First Drug FDA Approved For Alopecia Areata
Executive Summary
The FDA approved baricitinib for the hair loss disorder despite safety concerns with JAK inhibitors. It carries the same warnings on risk of CV events and malignancy as the others in the class.
You may also be interested in...
Lilly Olumiant Alopecia Launch Plans Focus On Disease Awareness And Coverage
Immunology president Patrik Jonsson talked to Scrip about being first to market with a systemic treatment for alopecia areata and launch plans for the new Olumiant indication.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: key takeaways from BIO; a new alopecia option in the US; how one small specialist company entered Japan; and the evolving BTK inhibitor landscape in multiple sclerosis.
Concert’s CTP-543 Shows Advantages Over Lilly, Pfizer Candidates For Alopecia
Concert’s deuterated ruxolitinib analog is potentially third in line to market for alopecia areata, behind Lilly’s Olumiant and a Pfizer JAK3 inhibitor, but may be demonstrating a best-in-class profile.